Coherus BioSciences (NASDAQ: CHRS) — Perfil da empresa, notícias e dados financeiros
Coherus BioSciences develops biosimilar therapies, focusing on oncology to improve access to essential medications for patients.
Coherus BioSciences
Coherus BioSciences (NASDAQ:CHRS) specializes in developing and commercializing biosimilar therapies, aiming to increase access to important medications for patients worldwide. The company operates in a highly competitive and regulated biopharmaceutical space, focusing on oncology and immuno-oncology products among other therapeutic areas. Coherus BioSciences' project pipeline is designed to challenge the status quo in medicine, with the objective of providing more affordable and accessible treatment options. Through strategic collaborations and in-house development, the company works tirelessly to bring transformative medications to market, reflecting its commitment to improving patient care and outcomes.
Resumo
Operações
Produtos e/ou serviços de Coherus BioSciences
- UDENYCA, a biosimilar to Neulasta, helps patients reduce the risk of infection following chemotherapy by stimulating white blood cell growth.
- CHS-1420, a Humira biosimilar, aimed at treating autoimmune diseases including rheumatoid arthritis.
- Yusimry, a biosimilar to vascular endothelial growth factor blocker Avastin, designed to treat various forms of cancer.
- A portfolio of immuno-oncology biosimilars aimed at providing more accessible treatments for cancer patients.
equipe executiva do Coherus BioSciences
- Dennis M. LanfearChairman, President & CEO
- Bryan J. McMichaelChief Financial Officer
- Carrie GrahamVice President of Investor Relations & Advocacy
- Andy RittenbergChief Legal Officer
- Rebecca SunshineChief Human Resources Officer
- Michael ChenSenior Vice President of Commercial Analytics & Trade
- Theresa M. LavalleeChief Development Officer & Chairman of Scientific Advisory Board
- Rosh DiasChief Medical Officer
- Arvind SoodChief Strategy & Corporate Affairs Officer
- Sameer GoregaokerChief Commercial Officer
Principais indicadores financeiros
Resultados divulgados pela Coherus BioSciences, em USD.
- Cap. de mercado
- 179,2 mi
- Receita (TTM)
- 50,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.3
- Dividend yield
- —
- Margem de lucro
- -259.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 42,2 mi | -179,5 mi | -170,3 mi | |
| 267 mi | -111,7 mi | 28,5 mi | |
| 257,2 mi | -203,2 mi | -237,9 mi | |
| 211 mi | -256,9 mi | -291,8 mi |